A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 81, Issue 3, 2007, Pages 271-277

  Groves, Morris D ^a   Puduvalli, Vinay K ^a   Chang, Susan M ^b   Conrad, Charles A ^a   Gilbert, Mark R ^a   Tremont Lukats, Ivo W ^a   Liu, Ta Jen ^a   Peterson, Pamela ^a   Schiff, David ^c   Cloughesy, Timothy F ^d   Wen, Patrick Y ^e   Greenberg, Harry ^f   Abrey, Lauren E ^g   DeAngelis, Lisa M ^g   Hess, Kenneth R ^a   Lamborn, Kathleen R ^b   Prados, Michael D ^b   Yung, Alfred W K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis inhibitors; Basic fibroblast growth factor; Clinical trial; Controlled; Glioblastoma multiforme; Interleukin 8; Temozolomide; Thalidomide; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; NITROSOUREA; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; KARNOFSKY PERFORMANCE STATUS; MALE; METASTASIS; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE WEAKNESS; NEUROSURGERY; NEUTROPENIA; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROBABILITY; SEIZURE; SIDE EFFECT; SKIN DISEASE; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORTH AMERICA; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 33846495120     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9225-y     Document Type: Article

References (34)

1. Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 6th edn. Lippincott, Williams and Milkins, Philadelphia, pp 2100-2160
2. Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635-644
3. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB (1993) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299-2304
4. Stewart LA (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018
5. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572
6. Brandes AA, Tosoni A, Amista P, Nicolardi L, Grosso D, Berti F, Ermani M (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281-1284
7. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593
8. Yung WK (2001) Future directions for temozolomide therapy. Semin Oncol 28:43-46
9. Osoba D, Brada M, Yung WK, Prados M (2000) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481-1491
10. Murray JJ, Greco FA, Wolff SN, Hainsworth JD (1983) Neoplastic meningitis - marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 75(2):289-294
11. Theodore WH, Gendelman S (1981) Meningeal carcinomatosis. Arch Neurol 38(11):696-699
12. King D, Goodman J, Hawk T, Boles ETJ, Sayers MP (1975) Dumbbell neuroblastomas in children. Arch Surg 110(8):888-891
13. Huang TY, Arita N, Ushio Y, Hayakawa T, Yamada K (1994) Pharmacokinetics of intrathecal 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rats. J Neurooncol 19(3):245-250
14. Teo SK, Stirling DI, Zeldis JB (2005) Thalidomide as a novel therapeutic agent: New uses for an old product. Drug Discov Today 10:107-114
15. Teo SK (2005) Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 7:E14-E19
16. List AF (2005) Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin Oncol 32:S31-S35
17. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680
18. Gelati M, Corsini E, Frigerio S, Pollo B, Broggi G, Croci D, Silvani A, Boiardi A, Salmaggi A (2003) Effects of thalidomide on parameters involved in angiogenesis: An in vitro study. J Neurooncol 64:193-201
19. Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H (2001) High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 7:2675-2681
20. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, Zhang Y, Liu Y, Li QQ (2003) Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23:2481-2487
21. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213-221
22. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG (2004) Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:229-243
23. Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg Neurol 49:189-195
24. Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, Berger M (1994) Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 18:207-216
25. Brat DJ, Kaur B, Van Meir EG (2003) Genetic modulation of hypoxia induced gene expression and angiogenesis: Relevance to brain tumors. Front Biosci 8:d100-d116
26. Reigstad LJ, Varhaug JE, Lillehaug JR (2005) Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 272:5723-5741
27. Harrigan MR (2003) Angiogenic factors in the central nervous system. Neurosurgery 53:639-660
28. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715
29. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353-357
30. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR (2001) Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54:31-38
31. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (2003) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597
32. Temodar (temozolomide) product information package insert. Schering Corp., Kenilworth, 2005
33. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
34. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003